Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 10/20 | 0.39 |
| ▸ | LCK | P06239 | 9/20 | 0.38 |
| ▸ | MET | P08581 | 8/20 | 0.38 |
| ▸ | TEK | Q02763 | 4/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857943 | 0.92 | NCF1 (0.38) | NCF1PIK3CAKDRLCKMET | |
| SCHEMBL856679 | 0.88 | PDE10A (0.42) | PIK3CAKDRPDGFRB | |
| SCHEMBL861578 | 0.88 | CREBBP (0.46) | PIK3CAGPR142CREBBP | |
| SCHEMBL3717304 | 0.86 | PIK3CA (0.42) | NCF1PIK3CAKDRLCKMET | |
| SCHEMBL857346 | 0.85 | NCF1 (0.45) | NCF1PIK3CAKDRLCKMET | |
| SCHEMBL7865632 | 0.85 | NCF1 (0.41) | NCF1PIK3CAKDRLCKMET | |
| SCHEMBL858428 | 0.82 | NCF1 (0.42) | NCF1PIK3CAKDRLCKMET | |
| SCHEMBL856104 | 0.81 | CREBBP (0.46) | PIK3CAGPR142CREBBP | |
| SCHEMBL3756056 | 0.80 | PIK3CA (0.43) | PIK3CAGPR142CREBBP | |
| SCHEMBL857760 | 0.80 | CLK4 (0.43) | PIK3CAGPR142PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |